NC
COLL icon

nVerses Capital’s Collegium Pharmaceutical COLL Stock Holding History

nVerses Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,700
Closed -$54.7K – 1066
2024
Q2 		$54.7K Buy
1,700
+1,600
+1,600% +$55.5K 0.03% 579
2024
Q1 		$3.88K Buy
+100
New +$3.5K 0.01% 600

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

nVerses Capital's COLL Position: Q3 2024 in Review

nVerses Capital sold out of Collegium Pharmaceutical (COLL) in Q3 2024, closing a stake of 1,700 shares — an estimated $54.7K sold.

nVerses Capital first reported a position in COLL in Q1 2024 and held it in 2 quarters. The position peaked at $54.7K in Q2 2024. 249 funds tracked by Wall St. Rank hold COLL as of Q3 2024.

  • nVerses Capital reported no remaining Collegium Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 1,700 Collegium Pharmaceutical shares in Q3 2024, an estimated $54.7K.
  • nVerses Capital first reported a position in Collegium Pharmaceutical in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Collegium Pharmaceutical position peaked at $54.7K in Q2 2024.
  • 249 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.